Molecular characterization of human HSPCs with different cell fates in vivo using single-cell transcriptome analysis and lentiviral barcoding technology
Junnan Hua , Ke Wang , Yue Chen , Xiaojing Xu , Guoyi Dong , Yue Li , Rui Liu , Yecheng Xiong , Jiabin Ding , Tingting Zhang , Xinru Zeng , Yuxi Li , Haixi Sun , Ying Gu , Sixi Liu , Wenjie Ouyang , Chao Liu
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (11) : e70085
Molecular characterization of human HSPCs with different cell fates in vivo using single-cell transcriptome analysis and lentiviral barcoding technology
•SCALeBa and its algorithm are developed to study the molecular mechanism underlying human HSPCs identity and function. | |
•The human HSPCs expressing MYL6B, MYO19, ATP2A2, MDN1, ING3, and PHF20 may have the capability for high stemness. | |
•The human HSPCs expressing COA3, RIF1, RAB14, and GOLGA4 may have the capability for pluripotent-lineage differentiation. | |
•The human HSPCs expressing MRPL23 and RBM4 genes may have the capability to differentiate into myeloid and lymphoid lineage respectively in vivo. | |
•The legitimacy of the identified genes with SCALeBa was validated using biological experiments and a public human HSPCs dataset. | |
•SCALeBa improves the accuracy of differentiation trajectories in monocle2-based pseudo-time analysis. |
barcoding technology / hematopoietic stem and progenitor cells / lineage tracing / scRNA-seq
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
/
| 〈 |
|
〉 |